Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL)

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Lurker Nancy reported acquisition or exercise transactions in this Form 4 filing.

Collegium Pharmaceutical director Nancy Lurker received a grant of 8,741 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest on the earlier of May 14, 2027, or the company’s 2027 annual shareholder meeting, if she continues serving as a director.

After this equity award, Lurker’s direct holdings total 26,758 shares of common stock. The RSUs will be settled in shares on vesting or, if she so elects, upon the earlier of her board service ending, her death or disability, or a change in control of Collegium Pharmaceutical.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lurker Nancy

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,741	$0.00	--

Holdings After Transaction: Common Stock — 26,758 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 8,741 RSUs Post-grant holdings: 26,758 shares Grant price per share: $0.00 per share +1 more

4 metrics

RSUs granted 8,741 RSUs Restricted stock units granted to director Nancy Lurker

Post-grant holdings 26,758 shares Common shares directly held after the RSU award

Grant price per share $0.00 per share Equity award granted at no cash cost to the director

Vesting date trigger May 14, 2027 Vests on this date or the 2027 annual meeting, whichever is earlier

Key Terms

restricted stock units ("RSUs"), contingent right, change in control, Annual Meeting of Shareholders

4 terms

restricted stock units ("RSUs") financial

"Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

change in control financial

"on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Annual Meeting of Shareholders financial

"on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lurker Nancy

(Last)

(First)

(Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON

MASSACHUSETTS

02072

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		A⁽¹⁾		8,741	A	$0	26,758	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

	/s/ Colleen Tupper as Attorney-In-Fact For Nancy Lurker	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Collegium Pharmaceutical (COLL) director Nancy Lurker report?

Nancy Lurker reported receiving 8,741 restricted stock units from Collegium Pharmaceutical. Each RSU represents a right to one common share, granted as equity compensation, increasing her direct holdings to 26,758 shares after the award.

How many shares does Nancy Lurker hold after her latest Collegium (COLL) RSU grant?

Following the 8,741-unit RSU grant, Nancy Lurker directly holds 26,758 shares of Collegium common stock. This figure reflects her position after the award, as disclosed in the Form 4 insider trading report.

When do Nancy Lurker’s newly granted Collegium (COLL) RSUs vest?

The 8,741 RSUs granted to Nancy Lurker vest on the earlier of May 14, 2027, or Collegium’s 2027 annual shareholder meeting. Vesting is conditioned on her continued service as a director through that date.

How will Nancy Lurker’s Collegium (COLL) RSUs be settled when they vest?

The RSUs will be settled in Collegium common shares at vesting or, if she elects, upon the earlier of her board service ending, her death or disability, or a change in control of the company, according to the Form 4 footnote.

Is Nancy Lurker’s Collegium (COLL) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant of 8,741 restricted stock units to Nancy Lurker at zero price, categorized as a grant or award acquisition. It is compensation-based, not an open-market stock purchase or sale.